The FDA Has Cleared Tonix Pharmaceuticals' Investigational New Drug Application For Phase 2 OASIS Trial For TNX-102 SL1 In Reducing The Severity Of Acute Stress Reaction And The Frequency Of Acute Stress Disorder And Posttraumatic Stress Disorder
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Tonix Pharmaceuticals' application for a Phase 2 trial of TNX-102 SL, aimed at reducing the severity of acute stress reactions and the frequency of acute stress disorder and PTSD. The trial is sponsored by UNC Institute for Trauma Recovery and supported by a $3 million DoD grant.
February 12, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals receives FDA approval for Phase 2 trial of TNX-102 SL for acute stress reactions, supported by a $3 million DoD grant.
FDA approval for a Phase 2 trial is a significant milestone for Tonix Pharmaceuticals, indicating regulatory confidence in TNX-102 SL's potential. The backing by a $3 million DoD grant not only adds financial support but also validates the importance of the study. This news is likely to be viewed positively by investors, potentially leading to a short-term increase in TNXP's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100